Montelukast
- Generic Name
- Montelukast
- Brand Names
- Singulair
- Drug Type
- Small Molecule
- Chemical Formula
- C35H36ClNO3S
- CAS Number
- 158966-92-8
- Unique Ingredient Identifier
- MHM278SD3E
- Background
Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs. Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticos...
- Indication
Montelukast is indicated for:
...
- Associated Conditions
- Asthma, Exercise-Induced Bronchospasm, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
- Associated Therapies
- -
Montelukast in Very Low Birthweight Infants
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 9
- Registration Number
- NCT00492102
- Locations
- 🇺🇸
Good Samaritan Hospital, Cincinnati, Ohio, United States
Montelukast With Status Asthmaticus, Ages 2-5
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2008-12-16
- Target Recruit Count
- 52
- Registration Number
- NCT00491790
- Locations
- 🇺🇸
Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma
- Conditions
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2007-06-28
- Lead Sponsor
- Medical University of Lodz
- Target Recruit Count
- 150
- Registration Number
- NCT00490243
- Locations
- 🇵🇱
Department of Pediatrics and Allergy, Medical University of Lodz, Poland, Lodz, Poland
Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation in Children With Allergic Rhinitis
- Conditions
- Interventions
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- Medical University of Lodz
- Target Recruit Count
- 116
- Registration Number
- NCT00488176
- Locations
- 🇵🇱
Department of Pediatrics and Allergy, Medical University of Lodz Lodz, Poland, Lodz, Poland
Comparison of Combination Therapy: Montelukast and Inhaled Steroid on Exercise Induced Bronchoconstriction
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2009-10-21
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT00462592
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇨🇦Hamilton Health Sciences-McMaster University, Hamilton, Ontario, Canada
Montelukast Back to School Asthma Study (0476-340)
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1162
- Registration Number
- NCT00461032
The Effect of Montelukast in Patients With Chronic Cough and Bronchial Hyperreactivity
- First Posted Date
- 2007-03-29
- Last Posted Date
- 2013-04-08
- Lead Sponsor
- Isala
- Target Recruit Count
- 89
- Registration Number
- NCT00453765
- Locations
- 🇳🇱
Isala Klinieken, Zwolle, Netherlands
Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2009-01-16
- Lead Sponsor
- Bernstein, Jonathan A., M.D.
- Target Recruit Count
- 6
- Registration Number
- NCT00406094
- Locations
- 🇺🇸
Bernstein Allergy Group, Cincinnati, Ohio, United States
Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)
- Conditions
- Interventions
- First Posted Date
- 2006-11-01
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 566
- Registration Number
- NCT00394355
Short- and Long Term Growth in Children With Asthma
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2008-02-27
- Lead Sponsor
- Children´s Clinic, Randers
- Target Recruit Count
- 52
- Registration Number
- NCT00380484
- Locations
- 🇩🇰
Children's Clinic Randers, Randers, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.